PolyPid CEO discloses stock option holdings
PolyPid Ltd. director and Chief Executive Officer Dikla Czaczkes Akselbrad filed an initial ownership report listing her existing equity position in the company.
Rhea-AI Filing Summary
PolyPid Ltd. director and Chief Executive Officer Dikla Czaczkes Akselbrad filed an initial ownership report listing her existing equity position in the company. The filing shows direct holdings of 934 Ordinary Shares and multiple stock options to buy additional Ordinary Shares at exercise prices ranging from 92.8900 down to 2.6700 per share, with expiration dates between 2026 and 2035. Several option grants are already fully vested, while others vest on a quarterly basis over future periods, indicating a mix of long-standing and more recent compensation awards rather than new market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
13 transactions reported
Mixed
13 txns
Insider
Akselbrad Dikla Czaczkes
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 575,386 contracts (Direct);
Ordinary Shares — 934 shares (Direct)
Footnotes (12)
- F1. The options were granted on April 5, 2016 and fully vested as of April 5, 2019.
- F2. The options were granted on August 24, 2016 and fully vested as of August 24, 2019.
- F3. The options were granted on December 21, 2016 and fully vested as of December 21, 2019.
- F4. The options were granted on May 5, 2023 and vest on a quarterly basis until May 5, 2027.
- F5. The options were granted on June 11, 2020 and fully vested as of July 1, 2022.
- F6. The options were granted on August 9, 2021 and vest on a quarterly basis beginning August 9, 2022 until August 9, 2025.
- F7. The options were granted on May 3, 2022 and fully vested as of April 1, 2025.
- F8. The options were granted on October 9, 2023 and vest on a quarterly basis beginning August 7, 2024 until August 7, 2027.
- F9. The options were granted on July 2, 2024 and vest on a quarterly basis until May 6, 2028.
- F10. The options were granted on July 2, 2024 and vest on a quarterly basis until May 6, 2026.
- F11. The options were granted on June 25, 2025 and vest on a quarterly basis until May 12, 2029.
- F12. The options were granted on June 25, 2025 and vest on a quarterly basis until May 12, 2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the PolyPid (PYPD) Form 3 filing by the CEO show?
The Form 3 shows CEO Dikla Czaczkes Akselbrad’s existing equity holdings in PolyPid. It lists directly owned Ordinary Shares and multiple stock options with specified exercise prices, vesting schedules, and expiration dates, providing a snapshot of her current compensation-linked exposure.
What types of stock options are reported for the PolyPid (PYPD) CEO?
The filing lists multiple stock options (rights to buy) Ordinary Shares with exercise prices of 92.8900, 117.9900, 23.0700, 11.0100, 4.6400, and 2.6700. These options form part of her compensation and can be exercised before their respective expiration dates.
Do the PolyPid (PYPD) CEO’s options in this Form 3 represent new purchases or sales?
No, the entries are categorized as holdings rather than new transactions. The Form 3 simply reports existing direct ownership of Ordinary Shares and outstanding stock options, without recording any new market purchases, sales, exercises, or other changes in position.
When do the PolyPid (PYPD) CEO’s reported stock options expire?
The reported stock options have expiration dates ranging from 2026 through 2035. For example, some grants expire in 2026, while later awards with lower exercise prices run out as far as 2035-06-25, defining how long they can be exercised.
How do the vesting terms of the PolyPid (PYPD) CEO’s options differ?
Some option grants are disclosed as fully vested by specific past dates, while others vest on a quarterly basis over future periods extending to 2029. This mix shows both already-usable awards and compensation that continues to vest over time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
